Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia.  Medinox retains the marketing rights in the United States, Japan and Europe.

NOX-100 is an investigative new drug developed by Medinox to treat conditions associated with excessive production of nitric oxide, such as in hemodialysis, cardiopulmonary bypass surgery and septic shock.  NOX-100, a small-molecule nitric oxide scavenger, binds nitric oxide and inactivates its properties.

Intradialytic hypotension (IH) is a significant complication of routine hemodialysis in end-stage renal disease patients. Complications of IH include headache, muscle cramps, and increase in mortalities.   At present, there is no FDA-approved therapy available for treating and/or preventing IH.

Medinox completed a Phase 1 safety study of NOX-100 in hemodialysis patients in the US. A Phase 2 trial of NOX-100 in hemodialysis will be conducted in Taiwan. This multicenter study will determine if NOX-100 lowers the incidence of IH, decreases the frequency of nurse intervention, and reduces the number of patient complaints and discomfort.  Over 380,000 end-stage renal failure patients in the US require dialysis.  In Taiwan, more than 60,000 patients are currently in dialysis.

Source:

 Medinox, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Elucidating the mechanisms behind kidney development